FDA funds UCSF-Stanford CERSI

The U.S. Food and Drug Administration has awarded the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (UCSF-Stanford CERSI) a five-year grant with up to $25 million in funding.

UCSF-Stanford CERSI brings together a world-class team of scientists from two outstanding academic institutions, with partners at the FDA, to spur new approaches and technology to enhance the FDA’s ability to evaluate and approve new medical products. The center also develops educational and research programs and fosters collaborations between scientists, faculty, students, and postdoctoral researchers at the FDA, UC San Francisco, and Stanford University.

The center is led by Kathy Giacomini, PhD, a faculty member in the Department of Bioengineering and Therapeutic Sciences, a joint department of the UCSF Schools of Pharmacy and Medicine, and Russ Altman, MD, PhD, a professor of bioengineering, genetics, and medicine at Stanford University. It was launched in 2014.

“This new funding is a strong vote of confidence from the FDA that we are on the right path in developing new models and methods for moving drugs and other medical products such as devices and cell-based therapies from the laboratory to clinical trials — not only more efficiently, but with greater confidence that they will be safe and effective,” Giacomini said.


FDA Funds UCSF-Stanford Center on Regulatory Science

About the School: The UCSF School of Pharmacy is a premier graduate-level academic organization dedicated to improving health through precise therapeutics. It succeeds through innovative research, by educating PharmD health professional and PhD science students, and by caring for the therapeutics needs of patients while exploring innovative new models of patient care. The School was founded in 1872 as the first pharmacy school in the American West. It is an integral part of UC San Francisco, a leading university dedicated to promoting health worldwide.